Fluorescence in situ hybridization (FISH) on interphase nuclei has been shown to be an efficient method for detecting aneuploidy in multiple myeloma (MM). The aim of this study was to test the feasibility of FISH techniques for detecting malignant cells in the harvests of MM patients submitted to autologous transplantation. As trisomy 9 (T9) is a frequent event in MM, we used it as a genetic marker of malignant plasma cells. T9 was detected in 45 out of 55 MM bone marrow samples (81.8%) using a chromosome 9 centromeric (C9C) probe. Twenty-four of the 55 MM patients were subjected to high-dose therapy followed by autologous unselected progenitor cell transplantation. Trisomy 9 was detected in 20 patients and was used as a marker of malignant cells. Upon karyotypic analysis, three of the four remaining patients without T9 showed an unbalanced translocation leading to a complete trisomy of the long arm of chromosome 1 (T1q). We thus used a 1q juxtacentromeric probe, pUC1.77, as another genetic marker of malignant plasma cells in these three further patients. FISH with C9C or pUC1.77 probes was performed on the harvests of these 23 patients and detected clonal cells in 11 transplants. The disease-free survival from graft was significantly longer for the patients who had no malignant cells in their transplant (P = 0.009). The median disease-free survival was 23 months in these patients, as compared to 12 months in the patients whose transplant was contaminated. As almost all MM are cytogenetically abnormal, FISH with adequate probes represents a simple, quantitative tool for rapid detection of malignant cells in the harvests. Our results also suggest that the presence of MM cells in the transplant may be predictive of poor outcome.
decade, new treatment strategies based on intensive chemotherapy with autologous progenitor cell support have been extensively proposed in order to improve the prognosis of these patients by achieving greater tumor load reduction and, as a result, longer disease control and possibly cure. These approaches showed that autologous transplantation increases complete response rates, event-free survival and overall survival. In newly diagnosed MM, complete response rates of 40-50% have been reported, but relapse remains a problem with an overall median progression-free survival of about 20 months. [2] [3] [4] [5] [6] [7] [8] Whether relapse is caused by residual malignant cells surviving in the patient after the conditioning regimen and/or by malignant plasma cells reinfused with the transplant remains unclear.
Recent emphasis has been placed on peripheral blood progenitor cell (PBPC) in preference to bone marrow (BM) for autologous transplantation. PBPC are easy to collect, harvests can be performed even in the case of a marrow heavily infiltrated with plasma cells and hematopoietic recovery is more rapid. Nevertheless, the consequences of PBPC contamination with MM cells cannot be neglected. Recent studies have shown that increased monoclonal plasma cells (у0.2 × 10 6 cells/l) in the PBPC harvest are associated with a shortened disease-free survival. 9 This justifies the interest towards developing techniques aimed at detecting and at quantifying malignant plasma cells in the harvest and in the patient after autograft. The challenge is the detection of minimal residual disease (MRD) in patients with an apparent complete response according to clinical, morphological and immunological criteria.
Conflicting levels of tumor cell contamination in the harvest have been reported, because of the diversity of the available methods for detection of malignant plasma cells. Tumor plasma cells may be identified by their morphology and their monotypic light chain staining using immunofluorescent microscopy. 9 Two-or three-color flow cytometry techniques have been developed to detect clonal plasma cells by their high CD38 positivity (CD38 bright cells), CD19 negative, CD56 and B-B4-positive phenotype and cytoplasmic immunoglobulin light chain restriction. [10] [11] [12] It was then demonstrated that the majority of plasma cells in PBSC harvests are polyclonal and that monoclonality is best detected on mature plasma cells. 13 Currently used molecular techniques are based on the detection of clonal immunoglobulin heavy chain (IgH) gene rearrangements by RT-PCR. Radioactive finger-printing PCR techniques looking for IgH gene tumor-specific rearrangements have found tumor cell contamination in up to 44% of harvests with a sensitivity of 10 Ϫ3 -10 Ϫ4 . 14, 15 Using an allele-specific oligonucleotide polymerase chain reaction technique with patient-specific complementary determining region III primers, 100% of patient samples were PCR positive for tumor cells even after a double transplant. 16, 17 Despite their high sensitivity (10 Ϫ6 ), these PCR methods are time-consuming, expensive and difficult to apply as a routine test.
Up to now, very few studies have been carried out using fluorescence in situ hybridization (FISH) for the detection of residual chromosomal aberrations in MM, 18 although chromosomal abnormalities are the hallmark of malignant plasma cells. FISH has already proven its efficiency in monitoring chimerism after allograft, 19 as well as in monitoring MRD after transplantation, in leukemia and lymphoma. [20] [21] [22] Recurrent chromosomal aberrations observed in MM include both numerical and structural alterations. Hyperdiploid cases usually show gains of chromosomes 3, 5, 7, 9, 11, 15, 19 whereas hypo/pseudodiploid karyotypes mainly involve structural abnormalities of chromosomes 1 11, 13, 14, 19, 22. 23,24 It has been shown that MM patients with hypo/pseudodiploid karyotype had a poorer outcome than those with a hyperdiploid karyotype. 25 Among chromosomal gains, trisomy 9 (T9) is the most 32 The aim of this study was to test the feasibility of FISH techniques for detecting MM cells in the harvest and for the follow-up of MM patients with known chromosomal abnormalities and who had been submitted to high-dose therapy. Interphase FISH with two probes, namely the chromosome 9 centromeric probe (C9C) and pUC1.77, marking the 1q12 region of chromosome 1, were used for this purpose.
Materials and methods

Patient selection and cell material
Twenty-four patients were enrolled in a protocol combining high-dose therapy with autologous unselected progenitor cell transplant. These patients were part of a series of 55 MM patients median age 63 years (range 32-85 years), 39 males and 16 females studied by karyotype and FISH with C9C referred to our laboratory between January 1995 and January 1998. Six patients were in stage I, four in stage II and 45 in stage III.
Twenty out of these 24 grafted patients had a trisomy 9 as detected by cytogenetic/FISH studies. Three other cases showed an unbalanced translocation involving the juxtacentromeric band 1q12 and leading to a trisomy of the long arm of chromosome 1 (T1q) as confirmed by FISH using the 1q12-specific probe, pUC1.77. As a whole, 23 of the 24 grafted patients had either a trisomy 9 and/or 1q and were included in this study (Table 1) .
Cytogenetic/FISH studies were first performed on mononuclear cells from bone marrow specimens either at diagnosis (UPN 9-23) or after a previous treatment (UPN [1] [2] [3] [4] [5] [6] [7] [8] . All patients were stage III MM, median age 57 years (range 46-65) and were enrolled in several multicentric French trials. 3, 5 Mononuclear cells of the harvests were studied by FISH after thawing. In seven patients (UPN 4, 9, 10, 12, 14, 15, 18), a FISH study was also carried out on bone marrow after intensification.
Treatment before intensification
Fifteen newly diagnosed patients (UPN 9-23) were harvested after an induction therapy with three or four cycles of vincristine, doxorubicin and dexamethasone (VAD). Patients who failed to respond after three VAD regimens (Ͻ50% of monoclonal protein) further received a cyclophosphamide-etoposide regimen before proceeding to PBPC collection. Four of these patients (UPN 8, 13, 14, 22) had a double intensification. The other eight patients (UPN 1-8) had previously been treated for more than 6 months with different lines of chemotherapy: (1) melphalan-prednisone; (2) VAD regimen; (3) alternating cycles of vincristine, melphalan, cyclophosphamide, prednisone (VMCP) and of carmustine, vincristine, doxorubicin, prednisone (BVAP). Patient 8 had a double intensification with PBPC support. After harvest, the patients had a VAD regimen prior to intensification.
PC harvest and cryopreservation
PBPC were collected by apheresis using a continuous flow cell separator (Baxter CS3000 (Baxter, Deerfield, IL, USA) or COBE Spectra (Cobe, Lakewood, CO, USA)). Patients received rhG-CSF at a dose of 8-10 g/kg/day, s.c. injection over 4-6 days. The cytokine was given until the end of collection, starting the apheresis on the 4th day of G-CSF, aiming at a minimum yield of Ͼ2 × 10 8 cells/kg; Ͼ1 × 10 5 CFU-GM/kg and Ͼ2 × 10 6 CD34 + cells/kg. The number of harvests ranged between one and three (mean two).
BM harvests were performed for four patients at 4 weeks after the last VAD regimen. Each collection was cryopreserved in 10% dimethylsulfoxide and 4% human serum albumin and stored in liquid nitrogen.
Conditioning regimen
Eighteen patients received total body irradiation (TBI) of 
Response to treatment and follow-up
Complete response (CR) was defined by the following criteria: (1) absence of serum and/or urine paraprotein as detected by electrophoresis and immunofixation; (2) 5% or fewer plasma cells of normal morphology on BM smears. Very good partial response (VGPR) was defined as a decrease of 90% in the serum paraprotein level, partial response (PR) as a decrease of 50% in the serum paraprotein level and/or a decrease of 90% in the urine BJ protein, and minimal response as a decrease of 25% in the serum paraprotein level. Progression (P) was defined as follows: (1) reappearance of detectable paraprotein and/or recurrence of bone marrow infiltration for patients in CR; (2) increase of at least 30% of the serum monoclonal protein level from the lowest level after transplantation (in case of Bence-Jones myeloma, doubling of urine monoclonal component); (3) occurrence of clinical and biological signs of MM (bone pains, new osteolytic lesions, cytopenia, hypercalcemia, renal failure).
At the time of the study (July 1998), nine of the 23 patients were dead (Table 1 ). In one case (UPN 14) death was caused by the toxicity of the conditioning regimen. Eleven patients (UPN 9-11, 13, 15-21) received interferon for 1 year (3 × 10 6 IU/day, 3 times/week) starting day 60 post autograft, when neutrophil recovery was Ͼ1 × 10 9 /l and platelet count was Ͼ80 × 10 9 /l. Some patients with poor response or progressive disease after transplantation (UPN 1-6, 8, 12 , 15, 18) received different chemotherapy schedules: VAD, vincristine-doxorubicin-BCNU, medium-dose cyclophosphamide, dexamethasone; patients 22, 23 received an allograft at relapse after autologous transplantation.
The 15 patients submitted to autotransplantation as firstline treatment (UPN 9-23) were all but five (UPN 12, 14, 15, 22, 23) good responders after three or four VAD regimens (Ͻ50% of monoclonal protein). Out of the eight patients receiving intensification as second-line treatment (UPN 1-8), six were in progression and two in minimal response (UPN 6 and 8) at the time of the harvest.
Cytogenetic/FISH study
Both unstimulated short-term cultures (48-72 h) and long term cultures (6 days) with GM-CSF 30 ng/ml, IL-6 10 ng/ml were set in RPMI 1640 supplemented with 15% fetal calf serum. Colchicine 0.04 g/ml was added overnight. Cells were given a hypotonic shock with KCl 0.075 m for 30 min at 37°C followed by three fixative changes (methanol:acetic acid 3:1). Chromosomes were analyzed with R banding. In each case, we attempted to analyze 40 metaphases. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN, 1995). 33 FISH was performed on cytogenetic pellet samples (bone marrow, harvests) with C9C and pUC1.77 probes. A first set of FISH tests was carried out with Spectrum Orangelabeled alpha-satellite DNA (D9Z1) chromosome 9-specific pericentromeric probe (CEP9, Vysis, Downers Grove, IL, USA), according to the manufacturer's instructions. A second set of FISH tests was performed with the pUC1.77 probe, hybridizing to the subcentromeric region 1q12. pUC1.77 was labeled by nick translation using biotin-16-dUTP (Boehringer, Meylan, France). Cytogenetic preparations were denaturated in 70% formamide, at 73°C, for 90 s. Three microliters of biotin-labeled pUC1.77 probe were resuspended in Hybrisol VI (Oncor, Gaithersburg, MD, USA) and denatured for 5 min at 70°C. Hybridization was performed at 37°C, for 6 h. Slides were then washed in 0.25 × SSC for 5 min at 72°C and rinsed in 4 × SSC/0.1% Tween 20. Detection was performed with FITC-avidin (Biosys, Compiègne, France).
Cells were counterstained with 4Ј,6-diaminido-2-phenylindole (DAPI) 0.5 g/ml final concentration in Vectashield antifading medium (Vector Laboratories, Burlingame, CA, USA) and examined using a Zeiss Axiophot epifluorescence microscope with a triple band pass filter (Zeiss, Oberkochen, Germany). Images were captured and analyzed using the ISIS MetaSystem imaging system (Metasystem, Altlussheim, Germany). For each sample, hybridization signals were scored blindly on at least 500 interphase nuclei and the percentage of nuclei with one, two, three and more than three spots was calculated. The control specimens for the C9C FISH study consisted of 20 normal bone marrow samples, five normal peripheral blood samples, and three PBPC samples from G-CSF-mobilized normal donors for allograft. Six normal BM samples, three normal peripheral blood samples and three PBPC samples from G-CSF-mobilized normal donors were used as controls for pUC1.77.
Statistical analysis
Fisher's exact test was used in order to evaluate if presence of T9 clonal cells in the infused transplant would influence the outcome of patients. Therefore the proportion of patients included in the two prognostic groups (good responders ie patients in VGPR or PR at the time of the study, and poor responders patients in progressive disease, irrespective of whether they had or not had an initial partial response) were compared with the two categories of infused transplants (T9/T1q free or positive).
Progression-free survival was estimated in the two groups of patients, receiving malignant cell-free or malignant cell-positive transplants, by using a log rank test.
Results
Interphase FISH results together with the main hematologic features regarding the follow-up of the 23 patients submitted to autologous transplantation included in that study are given in Table 1 . It should be noted that patient complete response was defined as absence of serum and/or urine paraprotein by both immunofixation and electrophoresis (see Materials and methods). Traces of monoclonal protein were thus detected in patients for whom electrophoresis was normal. Consequently, in this series, none of the 23 patients submitted to autograft obtained true CR. 34 However, the eight patients included in the VGPR group after transplantation presented no clinical and biological signs of progression, normal BM, normal electrophoresis.
FISH controls values
At least 500 interphase cells per control sample were scored. Nuclei with three C9C signals were revealed in 0-1.4% (mean 0.5%; s.d 0.5%) of bone marrow samples and in 0-0.6% (mean 0.4%; s.d. 0.2%) of normal peripheral blood samples or G-CSF-mobilized PBPC samples from normal donors. In order to avoid false positive results and taking into account the experience with centromeric probes, [20] [21] [22] 35, 36 the cut-off level for the presence of T9 (defined as the mean percentage of three-spot nuclei plus 3 s.d.) was fixed at 2%.
Using pUC1.77 probe, three-signal nuclei were revealed in 0-0.8% of the BM controls (mean 0.37%; s.d. 0.37%) and 0-0.65% of blood controls (mean 0.3%; s.d. 0.2%). The cut-off level for the presence of three-signal nuclei was fixed at 1.5% for both BM and PBPC samples. Correlation between karyotype and FISH study with C9C in the 55 patients is presented in Table 2 . When T9 was detected by karyotyping (n = 25), this finding was always confirmed by FISH; the percentage of T9 cells in these cases was higher than 18%. In addition, interphase FISH detected trisomy 9 in seven of the 12 patients with an abnormal karyotype and no karyotypically visible additional chromosome 9. Upon analysis of the few metaphase cells present on the slides of these seven cases, FISH allowed the identification of some cytogenetic markers as partial trisomy 9 in five of them. In five patients with abnormal karyotypes, T9 was not detected by either technique. FISH allowed detection of T9 in seven out of eight patients with cytogenetic failures (unsuccessful karyotype or less than 20 normal metaphases) and in six out of 10 patients with a normal karyotype (at least 20 metaphases studied). In these six patients, the percentage of T9 cells was lower than 18%.
Karyotype/FISH before intensification
The mean percentage of cells with trisomy 9 in the BM of patients 1-20 before harvest was 29.6% (range 8.4-59.4%). Trisomy 9 was confirmed by karyotyping in 14 of these patients. The other six patients were either cytogenetic failures or were cytogenetically normal.
In the BM of patients 21-23, evaluated by FISH with the pUC1.77 probe before harvest, the percentage of threesignal cells was 41.0%, 16.0% and 10.2%, respectively.
FISH detection of malignant plasma cells in the transplant
Outcome of patients: Interphase FISH was performed on 21 PBPC and four BM harvests after thawing. Trisomy 9 was detected at a significant level in seven out of 19 PBPC harvests (UPN 2, 3, 5, 6, 8, 15, 18) ( Table 1 ). The mean percentage of T9 cells was 5.1% (range 2.6-7%). In five other harvests (UPN 1, 11, 14, 17, 19) , the percentage of three-signal nuclei was below the established cut-off level. They were considered as T9-free harvests. In seven patients ( UPN 4, 7, 9, 12, 13, 16, 20) , no three-signal nuclei were detected. Two BM harvests (UPN 13 and 14) contained T9 cells at a significant level (9.6% and 2.6%, respectively), and one (UPN 10) was T9 free. Interestingly, patient 13 had a T9-free PBPC harvest but a T9-positive BM harvest.
Only one of the two PBPC harvests (UPN 23) tested with pUC1.77 probe presented three-signal nuclei at a significant level (6%). The BM transplant of patient 22 contained 3% of three-signal nuclei. The PBPC transplant of patient 16 was negative for both C9C and pUC1.77 probes.
The outcome of the patients after the graft and the relationship with the presence of malignant plasma cells (marked by either C9C or pUC1.77) in the infused harvest are shown in Table 3 . Ten out of the 11 patients with malignant plasma cells in the transplant were poor responders: seven of them (UPN 2, 3, 6, 8, 14, 22, 23 ) died 4-27 months after transplantation (death was caused by MM progression in six patients, for one patient a toxic death was registered), three patients (UPN 5, 15, 18) are alive with progressive disease at the time of study; only one patient having received a contaminated transplant is still in VGPR (UPN 13). In contrast, all but four of the 12 patients with uncontaminated infused transplant have been good responders (VGPR, n = 7; PR, n = 1). Two of the four poor-responders in this group (UPN 12, 21) are still alive, 27 and 15 months, respectively, after the graft. The two others (UPN 1, 4) died 8 and 2 months, respectively, after the transplantation. Fisher's exact test showed that the infusion of malignant plasma cells in the transplant is associated with progressive disease (P Ͻ 0.001).
Median progression-free survival (Figure 1 ) was significantly (P = 0.009) shorter for patients receiving contaminated harvests (12 months) when compared with the uncontaminated group (24 months).
Follow-up of malignant plasma cells in the BM:
Seven patients had a follow-up by FISH on BM samples after transplantation (Table 4) . No malignant plasma cells were detected after intensification in a total of three patients: UPN 9 and 10 are in VGPR, 34 and 31 months, respectively, after transplantation; UPN 14 died 4 months after intensification of infectious complications after a prolonged aplasia. For the other four patients (UPN 4, 12, 15, 18) , the percentage of T9 cells decreased from 33.6%, 56%, 20.2% and 28.3% to 11%, 22%, 16% and 6%, respectively 2, 4, 11 and 12 months after transplantation. In patient 12, after an initial decrease to 22%, 4 months after intensification, the percentage of T9 cells increased to 63% (the percentage of T9 cells at diagnosis was 56%), 14 months after the graft.
Discussion
The introduction, more than a decade ago, of high-dose chemotherapy was a turning point in the treatment of myeloma. Autologous PC transplants, including total body irradiation, high doses of melphalan (up to 200 mg/m 2 ) and tandem transplants have progressively increased CR rates, event-free survival and overall survival.
2-8 A major potential problem of autologous transplantation in MM is autograft contamination. It has been suggested that the use of G-CSF for mobilizing peripheral blood stem cells has the potential risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. 37 Both residual malignant cells surviving in the patients after the conditioning regimen and the contaminating malignant cells in the graft may be involved in relapse. 38 To resolve these issues, efficient methodologies for detection of even small numbers of tumor cells are required. This prompted us to evaluate an interphase FISH method for detecting and quantifying residual malignant plasma cells. This technique is simple Abbreviations as defined in Table 1 .
and rapid and could be applied also to monitoring of malignant plasma cells in the BM after transplantation. In this study, out of the 55 MM patients studied by FISH with C9C, trisomy 9 was detected in 45 patients (81.8%), irrespective of the clinical stage (Table 2 ). This confirms that T9 is a frequent and early chromosomal change in MM. 39, 40 Used as a complementary method to karyotypic analysis, FISH allowed detection of T9 in cases with unsuccessful (7/8) or normal (6/10) karyotype. These discrepancies between conventional cytogenetics and FISH results are mainly due to the proliferative advantage of normal myeloid BM cells and to the low proliferative rate of malignant plasma cells. 26 In seven cases, T9 was detected by FISH, but absent from the abnormal karyotype. In five cases, this discrepancy may be accounted for by the presence of marker chromosomes which turned out to contain genetic material from chromosome 9 (partial T9). In the two remaining cases, no such marker was found but the percentage of T9-positive cells in those samples was consistently lower than 18%, suggesting subclones. In our experience, the clonal numerical aberrations in MM are very stable and persist throughout tumor progression. Acquisition of T9 during tumor progression may certainly arise. However, very few cytogenetic/FISH studies on clonal evolution in MM are available and this hypothesis needs to be confirmed.
An unbalanced translocation 1q12 was detected by karyotyping in 16 of the 55 patients (29.1%) and confirmed by FISH with pUC1.77 probe in all 16 cases. Only three of these patients did not present a trisomy 9.
Overall, 23 the 24 patients (95.8%) submitted to autologous transplantation had trisomy 9 or trisomy 1q as FISH markers of MM cells. The remaining patient had a translocation t (11;14) , which means that all grafted patients had known chromosomal abnormalities, detectable by FISH/ cytogenetic techniques.
None of the patients under study received chemotherapy as the mobilizing protocol. It has been demonstrated that mobilization by cyclophosphamide plus G-CSF leads to a lower number of malignant cells in the harvest compared to G-CSF alone. 41 This might be one reason for the level of malignant plasma cells detected in the graft being higher than that reported by other authors. 42 Out of the 15 patients (UPN 9-23) submitted to PBPC transplantation as first-line treatment, nine received uncon-taminated harvests; the harvests of the other six patients contained T9 cells at a significant level. Only two out of the nine patients in the first group are in progression ( UPN 12, 21) ; the other seven are in remission 12 months or more after the graft. Five of the six patients in the second group are in progression or dead. Five of the eight patients receiving PBPC transplantation as second-line treatment had malignant plasma cells in their harvest. All five progressed. Of the other three patients who did not show malignant plasma cells in the harvest, one (UPN 7) is still alive in PR, 36 months after the graft.
Fisher's exact test (P Ͻ 0.001) and the curves of progression-free survival (Figure 1) show that the presence of clonal cells in the harvest is more frequently associated with progressive disease after transplantation. It would therefore appear that absence of malignant plasma cells in the transplant indicates a good prognosis whereas T9 or T1q positivity generally predicts a poor outcome. These results are in agreement with those reported by Gertz et al 9 using immunologic markers.
In spite of its relatively low sensitivity, the interphase FISH technique presented here represents a considerable advance over existing immunologic or molecular methods for detection of MM tumor cells in transplantation. For routine diagnosis, immunologic methods are hampered by the lack of specific tumoral markers and their low sensitivity. Quantitative PCR techniques based on the detection of IgH gene clonal rearrangements albeit specific are technically difficult and time-consuming and can be oversensitive, clonal cells often being detected in all transplants. By comparison, FISH analysis using clonal chromosomal markers and appropriate threshold values is a rapid and relatively simple quantitative method for assessing transplant contamination in a routine clinical setting. As for the abovementioned methods, a study at the time of diagnosis (karyotype/FISH) is necessary in order to select the potential chromosomal markers used in further FISH studies. In case of karyotype failure, a panel of two or three probes corresponding to the chromosomes more frequently gained (ie 9, 15, 3) or more often involved in structural rearrangements (ie, 1q12 and 14q32) could ensure a fairly good covering of typical cytogenetic profiles in MM.
The problem of progression/relapse of MM after autograft may be due to the malignant cells in the graft or to residual malignant cells surviving in the patients after the conditioning regimen. Because tumor cells are present not only in bone marrow, but also in virtually all PBPC harvests, it is conceivable that autografted myeloma cells contribute to relapse after autotransplants. In order to decrease the tumor load in the harvest, several researchers have proposed the purification of the progenitor cell material. 4, 7, 43, 44 However, the usefulness of purging autografts remains uncertain since attempts to assess the efficacy of purging procedures in myeloma have been limited by the lack of sensitive and quantitative techniques to detect small numbers of residual tumor cells after purging. The technique proposed in the present paper might prove to be instrumental in clarifying this problem.
Furthermore, this method has potential as a tool for quantifying tumor load in BM of autografted MM patients. Indeed, for seven of the 23 patients studied, the interphase FISH method was employed for monitoring the presence of T9 following transplantation. Of these, the two patients still in VGPR at 25 and 26 months, respectively, are T9 negative. Application of the proposed FISH technique on larger series of patients (at diagnosis, in the harvest and after transplantation) will help to define the kinetics of clonal plasma cells and relationship between progression and, as in the present study, contamination of the harvest.
Even if less sensitive than PCR, interphase FISH proved to be a simple, rapid and simple technique for detecting and quantifying clonal plasma cells in the harvest and in the bone marrow after transplantation.
